132 related articles for article (PubMed ID: 38394307)
1. The accuracy of 10 g monofilament use for clinical screening of diabetes peripheral neuropathy among Indian population.
Hazari A; Mishra V; Kumar P; Maiya A
PLoS One; 2024; 19(2):e0297110. PubMed ID: 38394307
[TBL] [Abstract][Full Text] [Related]
2. Validation of Neuropad in the Assessment of Peripheral Diabetic Neuropathy in Patients with Diabetes Mellitus Versus the Michigan Neuropathy Screening Instrument, 10g Monofilament Application and Biothesiometer Measurement.
Zografou I; Iliadis F; Sambanis C; Didangelos T
Curr Vasc Pharmacol; 2020; 18(5):517-522. PubMed ID: 31340739
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of prevalence and association of peripheral neuropathy in Indian patients with newly diagnosed type 2 diabetes mellitus.
Gill HK; Yadav SB; Ramesh V; Bhatia E
J Postgrad Med; 2014; 60(3):270-5. PubMed ID: 25121366
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the diagnostic accuracy of Vibrasense compared to a biothesiometer and nerve conduction study for screening diabetic peripheral neuropathy.
Sharma K N S; Kumar H A
J Foot Ankle Res; 2023 Sep; 16(1):65. PubMed ID: 37770911
[TBL] [Abstract][Full Text] [Related]
5. SUDOSCAN in Combination with the Michigan Neuropathy Screening Instrument Is an Effective Tool for Screening Diabetic Peripheral Neuropathy.
Oh TJ; Song Y; Jang HC; Choi SH
Diabetes Metab J; 2022 Mar; 46(2):319-326. PubMed ID: 34525791
[TBL] [Abstract][Full Text] [Related]
6. Prediction of incident diabetic neuropathy using the monofilament examination: a 4-year prospective study.
Perkins BA; Orszag A; Ngo M; Ng E; New P; Bril V
Diabetes Care; 2010 Jul; 33(7):1549-54. PubMed ID: 20357373
[TBL] [Abstract][Full Text] [Related]
7. Abnormal vibration perception threshold alters the gait features in type 2 diabetes mellitus patients.
Dong L; Hu Y; Xu L; Zeng H; Shen W; Esser P; Dawes H; Liu F
Front Endocrinol (Lausanne); 2022; 13():1092764. PubMed ID: 36844372
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive assessment of vibration perception and protective sensation in people with diabetes mellitus: inter- and intra-rater reliability.
Lanting SM; Spink MJ; Tehan PE; Vickers S; Casey SL; Chuter VH
J Foot Ankle Res; 2020; 13():3. PubMed ID: 31988664
[TBL] [Abstract][Full Text] [Related]
9. Mobile phone generated vibrations used to detect diabetic peripheral neuropathy.
May JD; Morris MWJ
Foot Ankle Surg; 2017 Dec; 23(4):281-284. PubMed ID: 29202988
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of diabetic peripheral neuropathy with use of the clanging tuning fork test.
Oyer DS; Saxon D; Shah A
Endocr Pract; 2007; 13(1):5-10. PubMed ID: 17360294
[TBL] [Abstract][Full Text] [Related]
11. Screening for peripheral neuropathies in children with diabetes: a systematic review.
Hirschfeld G; von Glischinski M; Blankenburg M; Zernikow B
Pediatrics; 2014 May; 133(5):e1324-30. PubMed ID: 24709928
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of peripheral neuropathy severe enough to cause a loss of protective sensation in a population-based sample of people with known and newly detected diabetes in Barbados: a cross-sectional study.
Adams OP; Herbert JR; Howitt C; Unwin N
Diabet Med; 2019 Dec; 36(12):1629-1636. PubMed ID: 31094005
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and feasibility of nailfold microcirculation test to screen for diabetic peripheral neuropathy.
Hu G; Zhai F; Mo F; He L; Shen W; Wang H
Diabetes Res Clin Pract; 2017 Sep; 131():42-48. PubMed ID: 28683299
[TBL] [Abstract][Full Text] [Related]
14. Inverse association between serum total bilirubin levels and diabetic peripheral neuropathy in patients with type 2 diabetes.
Kim ES; Lee SW; Mo EY; Moon SD; Han JH
Endocrine; 2015 Nov; 50(2):405-12. PubMed ID: 25846483
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Predictors of Diabetic Peripheral Neuropathy in Newly Diagnosed Type 2 Diabetes Mellitus Patients.
Jadhao P; Swain J; Das S; Mangaraj S; Sravya SL
Curr Diabetes Rev; 2024 Feb; ():. PubMed ID: 38347769
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic.
Olaleye D; Perkins BA; Bril V
Diabetes Res Clin Pract; 2001 Nov; 54(2):115-28. PubMed ID: 11640995
[TBL] [Abstract][Full Text] [Related]
17. Corneal confocal microscopy predicts 4-year incident peripheral neuropathy in type 1 diabetes.
Pritchard N; Edwards K; Russell AW; Perkins BA; Malik RA; Efron N
Diabetes Care; 2015 Apr; 38(4):671-5. PubMed ID: 25573881
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between serum cystatin-C levels and vibrating perception threshold in patients with
Type 2 diabetes mellitus].
Yan P; Zhang Z; Xu Y; Wan Q; Ma H; He J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Jan; 41(1):58-64. PubMed ID: 26819426
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of clinical tools and their diagnostic use in distal symmetric polyneuropathy.
Pourhamidi K; Dahlin LB; Englund E; Rolandsson O
Prim Care Diabetes; 2014 Apr; 8(1):77-84. PubMed ID: 23664849
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Glycated Hemoglobin and Vibration Perception Threshold in Diabetic Peripheral Neuropathy.
Maiya AG; Parameshwar A; Hande M; Nandalike V
Int J Low Extrem Wounds; 2020 Jun; 19(2):120-124. PubMed ID: 31838926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
